Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Nalbuphine Injection in Healthy Chinese Volunteers
NCT06902103Phase 1Completed
- Sponsor
- Yangtze River Pharmaceutical Group
- Start
- Dec 2023
- Primary completion
- Dec 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of nalbuphine in pain (2 arms), sponsored by Yangtze River Pharmaceutical Group. Primary endpoints: Maximum Drug Plasma Concentration up to 12 hours, Area Under the Curve from Time 0 to Last Quantifiable Concentration up to 12 hours and 6 more. Started Dec 2023; status: completed.
02
Drugs
nalbuphine
03
Conditions
pain
Beyond the preview
Go deeper on NCT06902103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06902103.